These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 24786925)

  • 21. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data.
    Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM
    Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.
    Emery P; Burmester GR; Bykerk VP; Combe BG; Furst DE; Barré E; Karyekar CS; Wong DA; Huizinga TW
    Ann Rheum Dis; 2015 Jan; 74(1):19-26. PubMed ID: 25367713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia(®) as Biological Intensive Treatment for RA (ORBIT) study.
    Tanaka Y; Kubo S; Yamanaka H; Amano K; Hirata S; Tanaka E; Nagasawa H; Yasuoka H; Takeuchi T
    Mod Rheumatol; 2014 Sep; 24(5):754-62. PubMed ID: 25036232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.
    Tanaka Y; Harigai M; Takeuchi T; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Baker D; Ishii Y; Yoshinari T;
    Mod Rheumatol; 2016 Jul; 26(4):481-90. PubMed ID: 26474192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.
    Huizinga TW; Conaghan PG; Martin-Mola E; Schett G; Amital H; Xavier RM; Troum O; Aassi M; Bernasconi C; Dougados M
    Ann Rheum Dis; 2015 Jan; 74(1):35-43. PubMed ID: 25169728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate.
    Takeuchi T; Matsubara T; Nitobe T; Suematsu E; Ohta S; Honjo S; Abe T; Yamamoto A; Miyasaka N;
    Mod Rheumatol; 2013 Mar; 23(2):226-35. PubMed ID: 22684431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
    Weinblatt ME; Schiff M; Valente R; van der Heijde D; Citera G; Zhao C; Maldonado M; Fleischmann R
    Arthritis Rheum; 2013 Jan; 65(1):28-38. PubMed ID: 23169319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
    Keystone EC; van der Heijde D; Kavanaugh A; Kupper H; Liu S; Guérette B; Mozaffarian N
    J Rheumatol; 2013 Sep; 40(9):1487-97. PubMed ID: 23818718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs.
    Takeuchi T; Matsubara T; Urata Y; Suematsu E; Ohta S; Honjo S; Abe T; Yamamoto A; Miyasaka N;
    Mod Rheumatol; 2014 Sep; 24(5):744-53. PubMed ID: 24754273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.
    Conaghan PG; Durez P; Alten RE; Burmester GR; Tak PP; Klareskog L; Catrina AI; DiCarlo J; Gaillez C; Le Bars M; Zhou X; Peterfy C
    Ann Rheum Dis; 2013 Aug; 72(8):1287-94. PubMed ID: 22915624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
    Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
    Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data.
    Dougados M; Schmidely N; Le Bars M; Lafosse C; Schiff M; Smolen JS; Aletaha D; van Riel P; Wells G
    Ann Rheum Dis; 2009 Apr; 68(4):484-9. PubMed ID: 19074177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis.
    Keystone EC; Kavanaugh A; Weinblatt ME; Patra K; Pangan AL
    J Rheumatol; 2011 May; 38(5):855-62. PubMed ID: 21285171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.
    Weinblatt M; Schiff M; Goldman A; Kremer J; Luggen M; Li T; Chen D; Becker JC
    Ann Rheum Dis; 2007 Feb; 66(2):228-34. PubMed ID: 16935912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
    Keystone EC; Haraoui B; Guérette B; Mozaffarian N; Liu S; Kavanaugh A
    J Rheumatol; 2014 Feb; 41(2):235-43. PubMed ID: 24293583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.